Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.34 |
| ▸ | RAF1 | P04049 | 13/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965165 | 0.91 | CYP2E1 (0.42) | CYP2E1NR1I2 | |
| SCHEMBL9961546 | 0.88 | CYP2E1 (0.49) | CYP2E1NR1I2 | |
| SCHEMBL1440071 | 0.88 | CYP2E1 (0.49) | CYP2E1NR1I2 | |
| SCHEMBL9965160 | 0.84 | CYP2E1 (0.44) | CYP2E1NR1I2 | |
| SCHEMBL10265042 | 0.82 | CYP2E1 (0.41) | CYP2E1MAPK14RAF1MAPTPKM | |
| SCHEMBL10265034 | 0.80 | CYP2E1 (0.45) | CYP2E1MAPK14RAF1MAPTPKM | |
| SCHEMBL9965161 | 0.79 | CYP2E1 (0.45) | CYP2E1NR1I2 | |
| SCHEMBL9961539 | 0.79 | CYP2E1 (0.59) | CYP2E1NR1I2 | |
| SCHEMBL1443545 | 0.79 | CYP2E1 (0.59) | CYP2E1NR1I2 | |
| SCHEMBL9965212 | 0.78 | NR1I2 (0.34) | MAPK14RAF1MAPTPKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | CYP2E1 6/4885MAPK14 2109/4885RAF1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.